US Patent Issued to IMMUNEXT on June 16 for "Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy" (British, American Inventors)

ALEXANDRIA, Va., June 16 -- United States Patent no. 12,653,884, issued on June 16, was assigned to IMMUNEXT INC. (Lebanon, N.H.).

"Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy" was invented by Jay Rothstein (Norwich, Vt.), Robert George Edward Holgate (Royston, Great Britain) and Arron Hearn (Ely, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "Improved anti-CD 154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammati...